Our results suggest that AXL signaling contributes to the aggressiveness of DDLPS and PLS, and that AXL is therefore a potential therapeutic target for treatment of these rare, yet devastating tumors. This evidence concerns the gene AXL and dedifferentiated liposarcoma.